14-day Premium Trial Subscription Try For FreeTry Free
$8.21
-0.290 (-3.41%)
At Close: May 07, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $5.34 $19.02 Tuesday, 7th May 2024 OTLK stock ended at $8.21. This is 3.41% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 7.10% from a day low at $8.17 to a day high of $8.75.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Nov 06, 2023 $0.458 $0.466 $0.432 $0.448 5 738 606
Nov 03, 2023 $0.340 $0.439 $0.340 $0.427 21 330 258
Nov 02, 2023 $0.259 $0.368 $0.250 $0.340 57 189 693
Nov 01, 2023 $0.593 $0.666 $0.593 $0.632 8 967 738
Oct 31, 2023 $0.537 $0.624 $0.537 $0.600 7 255 399
Oct 30, 2023 $0.506 $0.551 $0.492 $0.543 6 160 429
Oct 27, 2023 $0.554 $0.614 $0.494 $0.500 7 507 878
Oct 26, 2023 $0.527 $0.570 $0.520 $0.534 5 534 199
Oct 25, 2023 $0.524 $0.565 $0.513 $0.530 4 720 249
Oct 24, 2023 $0.446 $0.557 $0.446 $0.550 12 869 598
Oct 23, 2023 $0.410 $0.480 $0.363 $0.463 12 458 781
Oct 20, 2023 $0.621 $0.634 $0.470 $0.482 21 726 110
Oct 19, 2023 $0.510 $0.90 $0.481 $0.660 125 146 041
Oct 18, 2023 $0.390 $0.540 $0.385 $0.472 20 939 287
Oct 17, 2023 $0.339 $0.398 $0.334 $0.397 7 071 259
Oct 16, 2023 $0.345 $0.358 $0.310 $0.347 6 066 064
Oct 13, 2023 $0.306 $0.359 $0.287 $0.325 13 956 041
Oct 12, 2023 $0.250 $0.280 $0.248 $0.274 6 327 670
Oct 11, 2023 $0.244 $0.254 $0.243 $0.254 2 916 082
Oct 10, 2023 $0.229 $0.254 $0.229 $0.248 4 633 229
Oct 09, 2023 $0.226 $0.233 $0.221 $0.231 2 083 221
Oct 06, 2023 $0.231 $0.231 $0.220 $0.228 3 058 854
Oct 05, 2023 $0.235 $0.235 $0.220 $0.228 3 106 422
Oct 04, 2023 $0.230 $0.238 $0.230 $0.237 2 737 048
Oct 03, 2023 $0.220 $0.239 $0.220 $0.238 4 200 521
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Golden Star

Ticker Date Change Price
TMO May 02 0.403% $571.25
STNG May 02 0.699% $71.50
DLR May 02 2.58% $140.15
RF May 02 0.97% $19.64
INVH May 02 0.87% $34.50
SMAR May 02 2.24% $38.39
BIRK May 02 0.650% $44.61
FTSL May 02 0.217% $46.11
VCSH May 02 0.287% $76.71
VRNT May 02 2.44% $30.78
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT